SCHEMBL5887458

SCHEMBL5887458

CCOC(=O)N1CCN(c2nc(C)c3ccc(=O)n(-c4ccc(C(=O)NCc5ccccc5)cc4)c3n2)CC1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 4/20 0.46
KMT2A Q03164 4/20 0.46
SMN1; SMN2 Q16637 4/20 0.44
CYP2C19 P33261 1/20 0.44
CTNNB1 P35222 2/20 0.43
TCF7L2 Q9NQB0 2/20 0.43
HTT P42858 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
ATM Q13315 1/20 0.42
KDM4E B2RXH2 2/20 0.41
MAPT P10636 2/20 0.41
ALDH1A1 P00352 2/20 0.41
LMNA P02545 1/20 0.41
HPGD P15428 1/20 0.41
CHRM2 P08172 1/20 0.41
CHRM5 P08912 1/20 0.41
CHRM3 P20309 1/20 0.41
PTPN11 Q06124 1/20 0.41
TP53 P04637 1/20 0.41
STAT1 P42224 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5887351 0.95 SMN1; SMN2 (0.43) MEN1KMT2ASMN1; SMN2CYP2C19CTNNB1
SCHEMBL5887316 0.92 SMN1; SMN2 (0.45) MEN1KMT2ASMN1; SMN2CYP2C19CTNNB1
SCHEMBL5886882 0.92 MAPT (0.43) MEN1KMT2ASMN1; SMN2CYP2C19HTT
SCHEMBL5887578 0.91 SMN1; SMN2 (0.42) MEN1KMT2ASMN1; SMN2CYP2C19CTNNB1
SCHEMBL5887394 0.91 ACHE (0.44) MEN1KMT2ASMN1; SMN2CYP2C19CTNNB1
SCHEMBL5887410 0.91 SMN1; SMN2 (0.46) MEN1KMT2ASMN1; SMN2CYP2C19CTNNB1
SCHEMBL5887675 0.90 SLC6A7 (0.44) MEN1KMT2ASMN1; SMN2CYP2C19MAPT
SCHEMBL5887142 0.90 SMN1; SMN2 (0.43) MEN1KMT2ASMN1; SMN2CYP2C19CTNNB1
SCHEMBL5886891 0.90 TP53 (0.44) MEN1KMT2ASMN1; SMN2CYP2C19CTNNB1
SCHEMBL5887652 0.90 SMN1; SMN2 (0.42) MEN1KMT2ASMN1; SMN2CYP2C19CTNNB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7019002-B2 Substituted on 8th position with benzoic acid, ester or amide groups; anticancer agents PHARMACIA & UPJOHN, S.P.A. (IT) 2006-03-28 US claimed
US-20040009993-A1 Pyridopyrimidinones derivatives as telomerase inhibitors PHARMACIA ITALIA S.P.A. 2004-01-15 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040009993-A1 Pyridopyrimidinones derivatives as telomerase inhibitors TERT, TERF2, TERF2IP MEN1 2183/4885KMT2A 1530/4885SMN1; SMN2 2219/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.